Previous studies show that AKR1C3 has been upregulated in abiratarone resistant tumors [32, 33], suggesting that, in the AR responsive phase, androgen biosynthesis is inhibited but that, in resistance phase, tumor cells acquire the capacity to overexpress AKR1C3 enzyme. The gene discussed is AR; the disease is neoplasm.